March 24, 2025

Monarez Tapped to Lead CDC

President Donald Trump nominates Susan Monarez as director of the CDC, track record and budget analysis provided.

Reuters

March 24, 2025

New State Model for Psilocybin Therapy

Read about the emergence of state-regulated psychedelic mushrooms in Colorado and their potential therapeutic applications.

KFF Health News

March 21, 2025

Vutrisiran Receives FDA Nod for ATTR Amyloidosis With Cardiomyopathy

The FDA approves vutrisiran (Amvuttra) as the first RNAi therapeutic to reduce cardiovascular events and mortality in adults with transthyretin-mediated (ATTR) amyloidosis with cardiomyopathy.

Conexiant

March 21, 2025

FDA Approves Guselkumab for Crohn’s Disease

The FDA has approved guselkumab (TREMFYA®) for moderately to severely active Crohn’s disease, supported by Phase 3 trial data showing clinical and endoscopic superiority over ustekinumab.

Conexiant

March 21, 2025

Metal Bites: Meat Stick Recall Expands

Chomps beef and turkey sticks pulled from shelves in multi-state recall after metal fragments discovered; manufacturer urges consumers to check lot codes and return affected products for refund.

Conexiant

March 18, 2025

Medtronic Recall: FDA Issues Highest-Risk Warning

The FDA has classified the recall of Medtronic’s Pipeline Vantage embolization devices as its most serious, citing risks of thrombosis, stroke, and death. The devices, used to treat brain aneurysms, have been linked to multiple patient injuries and fatalities.

Reuters

March 18, 2025

FDA Approves First Liquid Losartan Formulation

FDA approves Arbli (TM), the first ready-to-use losartan oral suspension for hypertension, stroke risk reduction, and diabetic nephropathy.

Conexiant

March 17, 2025

Incyte’s Povorcitinib Shows Mixed Phase 3 Results

Incyte's povorcitinib, an oral JAK1 inhibitor, demonstrates promising results in phase 3 trials for hidradenitis suppurativa, potentially offering a new alternative treatment option.

Reuters

March 14, 2025

FDA Warns of Nitrous Oxide Misuse

The FDA warns of serious health risks associated with non-medical use of nitrous oxide, highlighting neurological damage, thromboembolic events, and death.

Reuters